A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies

dc.contributor.authorHärkönen Jouni
dc.contributor.authorPölönen Petri
dc.contributor.authorDeen Ashik Jawahar
dc.contributor.authorSelvarajan Ilakya
dc.contributor.authorTeppo Hanna-Riikka
dc.contributor.authorDimova Elitsa Y.
dc.contributor.authorKietzmann Thomas
dc.contributor.authorAhtiainen Maarit
dc.contributor.authorVäyrynen Juha P.
dc.contributor.authorVäyrynen Sara A.
dc.contributor.authorElomaa Hanna
dc.contributor.authorTynkkynen Niko
dc.contributor.authorEklund Tiia
dc.contributor.authorKuopio Teijo
dc.contributor.authorTalvitie Eva-Maria
dc.contributor.authorTaimen Pekka
dc.contributor.authorKallajoki Markku
dc.contributor.authorKaikkonen Minna U.
dc.contributor.authorHeinäniemi Merja
dc.contributor.authorLevonen Anna-Liisa
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code2607100
dc.converis.publication-id179055654
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/179055654
dc.date.accessioned2025-08-27T22:11:41Z
dc.date.available2025-08-27T22:11:41Z
dc.description.abstract<p>The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data.<br></p>
dc.identifier.eissn2213-2317
dc.identifier.jour-issn2213-2317
dc.identifier.olddbid201778
dc.identifier.oldhandle10024/184805
dc.identifier.urihttps://www.utupub.fi/handle/11111/49602
dc.identifier.urlhttps://doi.org/10.1016/j.redox.2023.102644
dc.identifier.urnURN:NBN:fi-fe2023033033885
dc.language.isoen
dc.okm.affiliatedauthorTalvitie, Eva-Maria
dc.okm.affiliatedauthorTaimen, Pekka
dc.okm.affiliatedauthorKallajoki, Markku
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier B.V.
dc.publisher.countryNetherlandsen_GB
dc.publisher.countryAlankomaatfi_FI
dc.publisher.country-codeNL
dc.relation.articlenumber102644
dc.relation.doi10.1016/j.redox.2023.102644
dc.relation.ispartofjournalRedox biology
dc.relation.volume61
dc.source.identifierhttps://www.utupub.fi/handle/10024/184805
dc.titleA pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S2213231723000459-main.pdf
Size:
11.54 MB
Format:
Adobe Portable Document Format